Codexis to Present Three siRNA Manufacturing Studies at TIDES Europe

Codexis, Inc. (NASDAQ: CDXS), a prominent provider of enzymatic solutions for therapeutics manufacturing, has announced its participation in the upcoming TIDES Europe annual meeting in Hamburg, Germany, from November 12-14, 2024. The company is set to present three significant data presentations that demonstrate the practical application of their ECO Synthesis™ manufacturing platform, which aids in the production of siRNA through both ligation and sequential enzymatic synthesis. Conference attendees can visit Codexis at Booth #709 in the exhibition hall.

The company will deliver a spotlight presentation titled "Process Development for Enzymatic Synthesis of RNAi Therapeutics" on Thursday, November 14, 2024, from 1:25 pm to 1:55 pm CET. Derek Gauntlett, Senior Director of ECO Synthesis Process Development, will be the keynote speaker. Additionally, Mathew Miller, PhD, Director of Life Science & RNA Technology, will present "RNA Synthesis Using Ligation for Improved Scalability and Reduced Manufacturing Cost" on Wednesday, November 13, 2024, from 3:55 pm to 4:10 pm CET. Codexis will also feature a poster presentation on "Engineered dsRNA ligases can efficiently scale siRNA manufacturing" for the duration of the conference in the Poster & Exhibit Hall.

RNAi therapeutics have gained substantial momentum due to the rise of mRNA vaccines and small interfering RNA (siRNA) candidates advancing in clinical trials. Traditional chemical synthesis methods for large-scale RNAi therapeutic production have faced challenges related to nucleic acid quality, quantity, and overall economics. With over 450 RNAi therapies in clinical development and more than 40 assets in Phase 2 and Phase 3 trials, the demand for RNAi therapeutics is expected to exceed current production capabilities by the end of the decade.

Codexis has developed the Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ platform to address these challenges by enabling commercial-scale RNAi therapeutic production through an enzymatic process. The platform was highlighted at the TIDES USA 2024 annual meeting, where Codexis demonstrated the enzymatic synthesis of a full-length sense strand of the oligonucleotide lumasiran, a commercially available siRNA therapeutic, as well as shorter sense strand fragments of another siRNA therapeutic asset, givosiran. The data highlighted Codexis's achievement of coupling efficiency greater than 98%, comparable to traditional phosphoramidite chemistry, and the enzymatic addition of a conjugation moiety to the lumasiran strand, with significantly fewer impurities.

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop, and enhance novel enzymes and other proteins. These enzymes address real-world challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The ECO Synthesis™ platform is part of Codexis's efforts to enable scaled RNAi therapeutic production through enzymatic processes, offering potential benefits such as higher yields, reduced energy usage and waste, improved manufacturing efficiency, and greater sensitivity in genomic and diagnostic applications.